70 days ago • Posted by William Ramstein
Medical-device tailwinds; industry ripe for deals.
For investors looking for exposure to health care without the risks involved with drug development and federal policy--J&J's massive cash and cash equivalents position as well as Stryker's, Medtronic's, and Abbott Labs' could help them strike important deals into the next year. With a combination of low rates and the end of the pandemic with the incoming vaccine, these outfits could continue to stir up the medical devices sector, and spill cash on new firms. See medical devices ETF performance since the end of March below.